By Sam Wightwick2026-11-20T10:11:00
A new study has revealed how the protein galectin-3 directly modifies amyloid fibril structure and drives microglial inflammation in Alzheimer’s disease.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-11-20T08:00:00Z
Contributor Dr Rahul Gupta, By Drug Target Review
2026-11-18T11:12:00Z
2026-11-18T07:00:00Z
Contributor Dr Bryan McClellan and Dr William Matsui, By Drug Target Review
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2023-09-27T13:56:39
Sponsored by Euretos
2026-09-24T06:30:00
Contributor Dr Dan Benjamin, By Drug Target Review
2026-05-25T07:00:00
Contributor Professor Neville Sanjana
2026-07-31T06:00:00
Contributor Dr Davinder Ramsingh, By Drug Target Review
2026-11-17T12:55:00Z By Sam Wightwick
2026-11-17T09:31:00Z By Sam Wightwick
2026-11-16T13:54:00Z By Sam Wightwick
2026-11-13T14:41:00Z By Sam Wightwick
Site powered by Webvision Cloud